Bifidobacterium breve MAK40B22B and Reduced Mortality Risk

• A randomised controlled trial of the probiotic Bifidobacterium breve BBG-001 in preterm babies to prevent sepsis, necrotising enterocolitis and death: the Probiotics in Preterm infantS (PiPS) trial.

  • 2016-08
  • RCT · n = 1,315
  • Health Technology Assessment 20(66)
  • • K. Costeloe
    • U. Bowler
    • P. Brocklehurst
    • P. Hardy
    • Paul Heal
    • E. Juszczak
    • A. King
    • N. Panton
    • F. Stacey
    • A. Whiley
    • M. Wilks
    • M. Millar

  • PubMed: 27594381
  • DOI: 10.3310/hta20660

  10 Insights on

  • Reduced Mortality Risk

  • High evidence
  • Large Human Trial
  • Infants

  There was no evidence of benefit for the primary outcomes {death: 8.3% vs. 8.5% [adjusted RR 0.93, 95% CI 0.67 to 1.30]}

  Effect

  Neutral

  Effect size

  Small

  Significant

  No